Souhaitez-vous accéder aux communiqués récents ?

New paper in Frontiers in Medicine reveals first reliable biomarker test for early kidney transplant rejection detection in living-donor recipients

Delray Beach, FL, March 04, 2026 (GLOBE NEWSWIRE) -- The Digital Biomarkers Market, valued at USD 4.10 billion in 2024, stood at USD 6.30 billion in 2025 and is projected to advance at a resilient...

MALVERN, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral...

Visera announces the official launch of MyVital ID, a consumer-focused wellness app to gather immediate insights into the wellness of its customers.

Tampa, FL, Jan. 14, 2026 (GLOBE NEWSWIRE) -- A new national survey of Alzheimer’s patients and caregivers reveals widespread gaps in support, communication, and access to emerging diagnostic...

MALVERN, Pa., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for...

Annovis attends CTAD 2025 with two presentations highlighting new biomarker data in Alzheimer's and Parkinson's diseases.

PALM BEACH, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The precision oncology sector is experiencing unprecedented transformation as biomarker-driven therapies and...

NEW YORK, NY, NEW HAVEN, CT, and PRINCETON, N.J., Nov. 19, 2025 (GLOBE NEWSWIRE) -- DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and...

Buntanetap significantly improves cognition in all Parkinson’s patients, with those exhibiting Alzheimer’s co-pathology showing a three-times greater response New data demonstrate reductions in...